For patients with advanced basal cell carcinoma (BCC) not curable by surgery, combining targeted drug therapy with radiation offers strong tumor control and long-term benefits. The drug (a Hedgehog pathway inhibitor like vismodegib) shrinks tumors and makes them more sensitive to radiation, while radiation destroys remaining cancer cells. A Phase II trial in patients with […]
USC biomedical engineers have created “EchoBack CAR T-cells,” smart immune cells that fight cancer up to five times longer than traditional CAR T-cells. This innovation could transform immunotherapy for solid tumors. These cells are activated by a brief ultrasound pulse at the tumor site and continue working for at least five days compared to just
Revolutionary Smart Immune Cells Deliver Long-Lasting Cancer Defense Read More »
Researchers at UC San Diego have developed DeepHRD, an AI tool that identifies homologous recombination deficiency in tumors from standard biopsy slides, achieving three times the accuracy of traditional genomic tests while avoiding their high failure rates. Retrospective studies show that precision medicine guided by such tools improves survival in breast, lung, and pancreatic cancers
Revolution in Cancer Care: AI, Precision Medicine, and Immunotherapy Read More »
A new personalized mRNA vaccine for pancreatic cancer is showing encouraging results in early clinical trials, offering hope against this highly lethal disease. The vaccine trains the immune system to recognize tumor-specific mutations, activating long-lasting T cells that persisted for nearly four years and reduced recurrence rates in responding patients, even during chemotherapy. Each vaccine
Pancreatic Cancer Vaccine Brings New Hope After Promising Early Trial Results Read More »
The AnnAraC combination of annamycin and cytarabine demonstrated encouraging activity in AML patients in the phase 1/2 MB-106 trial, suggesting potential survival benefits. Across first- through seventh-line settings, the median overall survival (OS) was nine months in the 22-patient intention-to-treat population. Patients achieving complete remission (CR, n=8) had a median OS of 15 months, with
PThe phase 3 monarchE trial demonstrates that adjuvant abemaciclib combined with two years of endocrine therapy significantly improves overall survival in high-risk, node-positive HR+/HER2– early breast cancer patients. The 7-year landmark analysis confirmed sustained benefits in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS). monarchE enrolled 5,637 patients across two cohorts. Cohort 1 (n=5,120)
The FDA has accepted the NDA for gedatolisib under its Real-Time Oncology Review program for HR+/HER2– advanced breast cancer, based on data from the phase 3 VIKTORIA-1 trial in PIK3CA wild-type patients. In the trial, gedatolisib plus fulvestrant and palbociclib reduced progression risk by 76% compared with fulvestrant alone (HR 0.24; P < .0001), achieving
FDA Accepts Gedatolisib NDA for Review in HR+/HER2–, PIK3CA Wild-Type Breast Cancer Read More »
Darolutamide (Nubeqa) is a novel therapy for metastatic castration-sensitive prostate cancer (mCSPC), a stage where cancer has spread but remains responsive to testosterone-lowering treatments. As a highly selective androgen receptor antagonist, it blocks male hormones that drive tumor growth while minimizing neurological side effects due to its limited penetration of the blood-brain barrier. The drug
Advanced stereotactic thermal ablation offers a minimally invasive, highly precise treatment for liver tumors. Using heat delivered through needle-like probes—either radiofrequency (RFA) or microwave (MWA)—this approach destroys cancer cells while sparing healthy tissue. Microwave ablation is especially effective for larger tumors due to faster, uniform heating unaffected by blood flow. Stereotactic systems enhance traditional ablation
Antibody-drug conjugates (ADCs) are targeted cancer therapies that combine a monoclonal antibody with a potent chemotherapy drug, delivering treatment directly to cancer cells while sparing healthy tissue. Often called “smart bombs,” ADCs improve outcomes across several cancers. An ADC works in four steps: the antibody binds specifically to cancer cell proteins, the complex is internalized,
Antibody-Drug Conjugates: Targeted Cancer Therapy in Clinical Practice Read More »